Newsletter Subject

IntelGenx: 8% Dividend and a Potential Drug Delivery Revolution 💊

From

investingchannel.com

Email Address

MarketsandMinds@news.investingchannel.com

Sent On

Thu, May 16, 2024 12:10 PM

Email Preheader Text

. What if you could invest in a healthcare startup offering an 8% dividend? But we?re not talking

[InvestingChannel Logo]( [Click to view in browser](. [Market and Minds Banner] *|MC_PREVIEW_TEXT|* [Intel-Gen-X-LOGO]( [Investment Opportunity: Be Part of IntelGenx's $510B Market Disruption]( What if you could invest in a healthcare startup offering an 8% dividend? But we’re not talking about a moonshot biotech that hopes to develop a compound that MIGHT work. [IntelGenx aims to disrupt the $510B pharmaceutical industry](…from the inside. Remarkable as it sounds, 40% of adults struggle with swallowing pills. IntelGenx’s oral film delivery system built off similar technology as Listerine strips, a product the chairman and founder co-invented. [Intel-Gen-X-Image-1]( This reimagined drug delivery method is faster, more efficient, and patient-friendly than current medication intake methods. IntelGenx is partnering with leading pharmaceutical companies to deliver their medications, potentially making IntelGenx the UPS to their Amazon. And now you can be a part of this opportunity. [IntelGenx preferred stock offering is available now on the My IPO platform](with a minimum investment of just $750. - 💸Hybrid Return Structure with 8% Dividend: 8% dividend plus the option to convert to common or 50% return on principal after 5 years if unconverted - 💰 Massive Potential Market: $510B market in the pharmaceutical industry - 💪Strong Pipeline: Over 80 issued and pending patents on the pipeline - 📉Advantageous Business Model: Provides pharma and biotech world with enabling technology vs. onerous spend on marketing and drug discovery. - 🌐Proven Technology & Pharma Veterans: Experienced leadership at top firms like Glaxo plus thin-film technology, reminiscent of dissolvable breath strips, to innovate in pharmaceutical delivery. Join the drug delivery revolution with IntelGenx. [CLICK HERE to receive your free Investor Deck and learn more about investing in IntelGenx.]( AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT IS AVAILABLE [HERE](. ADDITIONAL INFORMATION CONCERNING[RISK FACTORS]( RELATED TO THE OFFERING CAN BE FOUND IN THE OFFERING CIRCULAR.THIS PAGE MAY INCLUDE ''FORWARD-LOOKING STATEMENTS.'' TO THE EXTENT THAT THE INFORMATION PRESENTED IN THIS PRESENTATION DISCUSSES FINANCIAL PROJECTIONS, INFORMATION, OR EXPECTATIONS ABOUT INTELGENX TECHNOLOGIES CORP (“INTELGENX”) BUSINESS PLANS, RESULTS OF OPERATIONS, PRODUCTS OR MARKETS, OR OTHERWISE MAKES STATEMENTS ABOUT FUTURE EVENTS, SUCH STATEMENTS ARE FORWARD-LOOKING. SUCH FORWARD-LOOKING STATEMENTS CAN BE IDENTIFIED BY THE USE OF WORDS SUCH AS ''SHOULD,'' ''MAY,'' ''INTENDS,'' ''ANTICIPATES,'' ''BELIEVES,'' ''ESTIMATES,'' ''PROJECTS,'' ''FORECASTS,'' ''EXPECTS,'' ''PLANS,'' AND ''PROPOSES.''ALTHOUGH INTELGENX BELIEVES THAT THE EXPECTATIONS REFLECTED IN THESE FORWARD-LOOKING STATEMENTS ARE BASED ON REASONABLE ASSUMPTIONS, THERE ARE A NUMBER OF RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM SUCH FORWARD-LOOKING STATEMENTS. YOU ARE URGED TO CAREFULLY REVIEW AND CONSIDER ANY CAUTIONARY STATEMENTS AND OTHER DISCLOSURES, INCLUDING THE STATEMENTS MADE UNDER THE HEADING "RISK FACTORS" AND ELSEWHERE IN THE OFFERING STATEMENT FILED WITH THE SEC. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE OF THE DOCUMENT IN WHICH THEY ARE CONTAINED, AND INTELGENX DOES NOT UNDERTAKE ANY DUTY TO UPDATE ANY FORWARD-LOOKING STATEMENTS EXCEPT AS MAY BE REQUIRED BY LAW.THE OFFERING WILL BE MADE ONLY BY MEANS OF AN OFFERING CIRCULAR. AN OFFERING STATEMENT ON FORM 1-A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION AND HAS BECOME QUALIFIED. THE SECURITIES OFFERED BY INTELGENX ARE HIGHLY SPECULATIVE. INVESTING IN SHARES OF INTELGENX INVOLVES SIGNIFICANT RISKS. THE INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT COULD BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET CURRENTLY EXISTS FOR THE SECURITIES, AND IF A PUBLIC MARKET DEVELOPS FOLLOWING THE OFFERING, IT MAY NOT CONTINUE. INTELGENX DOES NOT INTEND TO PUBLICLY LIST ITS PREFERRED STOCK. ADDITIONAL INFORMATION ON INTELGENX , THE OFFERING AND ANY OTHER RELATED TOPICS, PLEASE REVIEW THE FORM 1-A OFFERING CIRCULAR THAT CAN BE FOUND BY SEARCHING FOR INTELGENX TECHNOLOGIES CORP. UNDER FILINGS/COMPANY FILINGS SEARCH ON WWW.SEC.GOV. ADDITIONAL INFORMATION CONCERNING RISK FACTORS RELATED TO THE OFFERING, INCLUDING THOSE RELATED TO THE BUSINESS, GOVERNMENT REGULATIONS, INTELLECTUAL PROPERTY AND THE OFFERING IN GENERAL, CAN BE FOUND IN THE RISK FACTOR SECTION OF THE FORM 1-A OFFERING CIRCULAR. --------------------------------------------------------------- PLEASE NOTE: InvestingChannel, Inc., and its employees are not a registered investment adviser, broker-dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. This Newsletter is operated by InvestingChannel, Inc. (“InvestingChannel”, “we” or “our”). Our website and newsletter are for entertainment purposes only. This newsletter is NOT a source of unbiased information. InvestingChannel does not provide investment advice, endorsement, analysis or recommendations with respect to any securities, and its services should never be construed as any endorsement of or opinion about any security. You are reading this Newsletter because you have subscribed via our Opt-In Signup form on InvestingChannel.com or one of our network partners' website. If you have been subscribed by mistake, you may unsubscribe [HERE](. This is a PAID ADVERTISEMENT provided to customers/subscribers of InvestingChannel.com. Although we have sent you this email, InvestingChannel.com does NOT endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. IMPORTANT DISCLAIMER: In accordance with Section 17(b) of the Securities Act of 1933, you are hereby advised that Investing Channel is being paid on a Cost-Per-Click basis which may exceed a fee of over $1000.00 in cash, from an unaffiliated third-party (“advertiser”) as compensation for the distribution of this advertisement. InvestingChannel.com has not determined if the statements and opinions of the advertiser are accurate, correct or truthful. The purpose of this advertisement, like any advertisement, is to provide publicity for the advertiser, its products or services. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated emails does not constitute investment, legal or tax advice upon which you should rely. The purchase of securities may result in the loss of your entire investment. You understand that this advertisement or our website constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. This advertisement is not a solicitation, offer, inducement, invitation or recommendation to buy securities, services or product of the advertiser. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. Advertisements distributed through disseminated emails are not disclosure documents. If you are considering purchasing any securities of the advertiser, you should call your state securities regulator to determine if the security may be sold in your state. You should read and review, if and to the extent available, any information concerning the advertiser available at the websites of the U.S. Securities and Exchange Commission (the "SEC") at and the Financial Industry Regulatory Authority (the "FINRA") at . Many companies have information filed with state securities regulators who may be able to supply you with additional information. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud available at as well as related information published by FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence. We strongly encourage you to conduct your own research before making any investments decisions. You agree and acknowledge that any hyperlinks to the website of (1) an advertised company, (2) the party issuing or preparing the information for the advertiser, or (3) other information contained in our disseminated emails is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of external websites, nor are we responsible for the content, advertising, opinions, products or other materials on external websites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated email, external website or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates, and agents harmless. You acknowledge that you are not relying on us, and we are not liable for any actions taken by you based on any information contained in any disseminated email, website or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any advertiser. InvestingChannel, Inc., P.O. Box 118, New York, NY 10018 [Link](

Marketing emails from investingchannel.com

View More
Sent On

08/12/2024

Sent On

08/12/2024

Sent On

06/12/2024

Sent On

06/12/2024

Sent On

04/12/2024

Sent On

04/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.